Don't forget to join @vigeotx.bsky.social
COO Jing Watnick speaking at the
#GBM summit in Boston at 1:30 EDT today. Dr. Watnick will speak on our Ph1/2 in GBM as well as the future use of #VT1021 in attacking the roots of #Neuroinflammatory disease. #glioblastoma #neurodegenerativedisease

Vigeo Therapeutics to Present at the 2024 Glioblastoma Drug Development Summit in Boston Massachusetts - Vigeo Cambridge MA – March 26, 2024 –Vigeo Therapeutics, a clinical-stage immuno-therapy company pioneering novel therapies to treat oncology and inflammatory diseases will be presenting at the Fifth Gliobl...

Don't miss the #VT1021 update from @vigeotx.bsky.social COO Jing Watnick at the #GBMSummit in Boston MA this week. Dr. Watnick will give an update on the #VT1021 Ph1/2 program in #GBM as well as potential future use of #VT1021 in Neuro-inflammatory disease #glioblastoma #neuroinflammatorydisease

Dr. Suming Wang of Vigeo Therapeutics presented a poster at the Crohn's and Colitis Congress in Las Vegas NV studying VT1021 efficacy in IBD models in mice. #VT1021 #TSP1 #IBD #crohnsdisease #cccongress24

vigeotx.com/wp-content/u...

So proud of the @vigeotx.bsky.social Team on the publication of our First in Human Phase 1 study with VT1021 in #NatureCommunicationsMedicine This paper is a great achievement showing the power of VT1021 treating solid tumors #CD36 #CD47 #VT1021 #NaturePortfolio
rdcu.be/dvUw8